ResultsIQ › Latest results › Nuvama Wealth Management Limited
Nuvama Wealth Management Limited Q3 FY26 earnings call summary
NSE: NUVAMA · BSE: 543988
Earnings call of 27 Jan 2026, summarised by AI from the filing.
Competitive intensity growing with PE-backed platforms moving into HNI and affluent segments.
Key takeaways
- Competition risk Competitive intensity growing with PE-backed platforms moving into HNI and affluent segments.
Nuvama Wealth Management Limited Q1 FY27 results
As filed: Revenue ₹1,376 cr (+23% year on year), EBITDA ₹724 cr (+19% year on year), PAT ₹306 cr (+16% year on year), EBITDA margin 52.6% (−178 bps).
The Q1 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q4 FY26: Revenue ₹1,269 cr (+13% year on year), EBITDA ₹629 cr (+9% year on year), PAT ₹269 cr (+5% year on year), EBITDA margin 49.5% (−181 bps). Score 27 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 181 bps year on year. Consolidated profit +5% but standalone -29%. Revenue rose ₹149 cr on a year ago, against ₹193 cr the year before. Share price after the results: −4.8% in 30 days (Nifty 500: −2.5%).
- Q3 FY26: Revenue ₹1,104 cr (+7% year on year), EBITDA ₹608 cr (+5% year on year), PAT ₹254 cr (+1% year on year), EBITDA margin 55.1% (−115 bps). Score 22 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 115 bps year on year. Share price after the results: +4.5% in 28 days (Nifty 500: +3.0%).
- Q2 FY26: Revenue ₹1,135 cr (+8% year on year), EBITDA ₹594 cr (+5% year on year), PAT ₹254 cr (−1% year on year), EBITDA margin 52.3% (−133 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 133 bps year on year. Profit fell 4% from last quarter. Revenue rose ₹84.0 cr on a year ago, against ₹316 cr the year before. Share price after the results: −1.0% in 30 days (Nifty 500: +0.3%).
- Q1 FY26: Revenue ₹1,123 cr (+18% year on year), EBITDA ₹611 cr (+24% year on year), PAT ₹264 cr (+19% year on year), EBITDA margin 54.4% (+246 bps). Score 69 of 100, Above trend. EBITDA margin rose 246 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.0% in 30 days (Nifty 500: +2.2%).
- Q4 FY25: Revenue ₹1,120 cr (+21% year on year), EBITDA ₹575 cr (+24% year on year), PAT ₹255 cr (+41% year on year), EBITDA margin 51.3% (+129 bps). Score 69 of 100, Above trend. EBITDA margin rose 129 bps year on year. Consolidated profit +41% but standalone -16%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +19.7% in 30 days (Nifty 500: +3.7%).
- Q3 FY25: Revenue ₹1,032 cr (+23% year on year), EBITDA ₹580 cr (+31% year on year), PAT ₹252 cr (+43% year on year), EBITDA margin 56.2% (+341 bps). Score 80 of 100, Above trend. EBITDA margin rose 341 bps year on year. Not enough history for a trend yet: scored on growth alone.
- Q2 FY25: Revenue ₹1,051 cr (+43% year on year), EBITDA ₹564 cr (+57% year on year), PAT ₹257 cr (+77% year on year), EBITDA margin 53.7% (+468 bps). Score 97 of 100, Above trend. EBITDA margin rose 468 bps year on year. Not enough history for a trend yet: scored on growth alone.
Past price moves after results do not indicate future moves. Not a recommendation.
Nuvama Wealth Management Limited earnings call, investor presentation and press release summaries
- Q1 FY27: Earnings call (31 Jul 2026), Results deck (30 Jul 2026), Results deck (5 Aug 2026)
- Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results deck (21 May 2026)
- Q3 FY26: Earnings call (27 Jan 2026), Results deck (23 Jan 2026), Results deck (4 Feb 2026)
- Q2 FY26: Earnings call (5 Nov 2025), Results deck (4 Nov 2025)
- Q1 FY26: Earnings call (14 Aug 2025), Results deck (13 Aug 2025)
- Q4 FY25: Earnings call (29 May 2025), Results deck (28 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.